Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. - Wikidata - awgldk - TriplyDB

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.

http://www.wikidata.org/entity/Q46748103

about

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer Gemcitabine for platinum-resistant or recurrent ovarian cancer Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?Adoptive immunotherapy against ovarian cancer Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.New developments in treatment of ovarian carcinoma: focus on trabectedin Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients.A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy.The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens.Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish.Pegylated liposomal doxorubicin in the management of ovarian cancer Pemetrexed disodium in ovarian cancer treatment.Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary.Major clinical research advances in gynecologic cancer in 2010 Emerging role of pemetrexed in ovarian cancer.Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy.Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer Anaphylaxis to pegylated liposomal Doxorubicin: a case report Synthesis, evaluation of anti-HIV-1 and anti-HCV activity of novel 2',3'-dideoxy-2',2'-difluoro-4'-azanucleosides Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer.Recent progress in the diagnosis and treatment of ovarian cancer A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study Health-related quality of life in ovarian cancer patients and its impact on clinical management Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer Latest research and treatment of advanced-stage epithelial ovarian cancer Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.Treatment of recurrent epithelial ovarian cancer

P2860

Q24201282-2587CEC7-2CE4-4778-AD16-2805090A2FEE Q24241162-1CC9992A-0588-4C35-A71D-A41824BE2E6E Q24633820-5D68C557-082B-41FE-B9FE-6F94E7ECF65F Q26742047-876762C1-A237-4A5F-9699-8104E4B87D84 Q26748905-2CB2DE97-572B-4F0E-A3FA-79E5EFFFD4A0 Q26858830-4FC2EFDD-E768-4156-965F-84F2DD796B84 Q30421664-90D78737-1F3D-41D7-848C-F00B7176F974 Q33383091-BBE690F9-503E-4635-9233-2C4AA009994D Q33393429-24D86C1A-1024-4318-84B1-165E4B78CFEF Q33393879-9DC779C7-62CD-421F-AD33-B1388C1EDD08 Q33395587-9FFCB9CD-C3DC-41E4-919D-074987072B9D Q33397131-A3C13442-0FFC-4D14-8E89-5D1B7870CF7E Q33409319-83C14ABF-B006-4539-9582-34BB5273674D Q33413585-B8F4714A-88F8-49B8-84A6-F863EF42E848 Q33437512-4E3001E5-565E-4FF4-851A-6BF98B513CCF Q33829859-C6D5ECB4-7B99-4891-9CBF-C541EDEE31D7 Q33857633-4562F8F8-D1D8-4547-A0B2-2C73498EFFED Q34187661-A4A1BA87-649C-465D-B5A3-EE8F301476D4 Q34253505-43DC7FA4-3B4B-4224-94C6-8302FC7B94C1 Q34300629-2F27192D-CD32-43B0-AD63-80B0F3FC691A Q34307937-A0ED4BA7-5DC9-4305-88A5-F602CA41A2D7 Q34517694-F68CF3A1-02E2-438A-BE13-E31154B7841B Q35015611-0B97A063-1504-4C46-954C-E24CB11F3BFA Q35114915-CEFD1E72-CAF9-498C-BF53-D331DFED96C8 Q35226511-363D7F3A-C8ED-46EC-9A6C-D4A31201D25F Q36106810-704FB2E8-503F-4B12-B33E-D63E725DE047 Q36166608-164D1693-4A07-48DF-A85B-9A448A1A2216 Q36330834-76E3B4C9-2A8F-4A92-81B2-5F926DD6DD28 Q36374005-84BBD8FC-BDCF-4544-ACD4-AE5615F95435 Q36400401-9EBBC52F-6B1D-493D-9A14-F490EEBB0E64 Q36584405-24045361-C96E-4629-BF81-DBA5C240688C Q36622857-CFA5CD2B-8E46-4EF2-AB97-97F0738804A8 Q36689744-8F6AEB12-E360-4D0C-AB95-3674738675CD Q36728989-7D79D01F-D7CC-4B04-9334-888E5B24B513 Q36843044-8FECD986-43E2-4EFB-B613-6D0531D20A24 Q37036780-F9EC42D8-1DCB-44DD-B94D-48CFD8D981AF Q37123465-7B803149-EF45-43C5-9EE1-40831726D664 Q37206348-73182939-9B15-4DE3-970C-BC631AD134CA Q37220528-C1704BDD-43B0-42F4-89A4-935E91716E0A Q37224624-21CB3E66-C6BE-4631-9D54-EFE8380C46C1

P2860

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.

http://www.wikidata.org/entity/Q46748103

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Phase III trial of gemcitabine ...... e or recurrent ovarian cancer.

@en

Phase III trial of gemcitabine ...... e or recurrent ovarian cancer.

@nl

type

label

Phase III trial of gemcitabine ...... e or recurrent ovarian cancer.

@en

Phase III trial of gemcitabine ...... e or recurrent ovarian cancer.

@nl

prefLabel

Phase III trial of gemcitabine ...... e or recurrent ovarian cancer.

@en

Phase III trial of gemcitabine ...... e or recurrent ovarian cancer.

@nl

P1433

Q46748103-26B35137-9DDA-422A-A1FF-CE43800703A7

P1476

Q46748103-26A59754-FC29-4676-95A8-1BD3D1E2EEEA

P2093

Q46748103-2DFD8BE2-ACA9-4B20-84E2-2D721DD1D935

Q46748103-3374F914-E3F2-49D5-91B3-6E48EB84814F

Q46748103-342B9F3E-0753-4F19-A76E-59250BAE3B0E

Q46748103-47BBE241-B914-41BF-BD82-485B538D4A43

Q46748103-60CC742C-BC18-4CC1-AB0E-518EB4D5DBD1

Q46748103-726F7615-1918-45A9-9403-30FF6CB3FBEA

Q46748103-84B9E6F5-7C21-479B-B1D6-46C12C3321DB

Q46748103-D1DFE0CC-B412-469F-8486-1A14C08ACA85

Q46748103-ECEA2AB1-AD4F-4E20-8BE6-CB467BCE3D08

P304

Q46748103-CD389D68-416B-479D-8822-0DBD197DC1A7

P31

Q46748103-2898CE69-4492-4A75-AF0D-9F55BE418986

P356

Q46748103-0438C794-0E8D-4C75-BBB3-2D9BC1047D83

P407

Q46748103-4536175A-DD87-4BDD-911E-FA6183A801D2

P433

Q46748103-BF87C66D-DA4E-4D9D-88AF-A6CA491F1A13

P478

Q46748103-E637C817-0D48-4D08-AC82-9B4B9B3AC802

P50

Q46748103-30085687-8C4E-41D8-97CC-2EED300464A6

Q46748103-B08C8E67-BC6A-46A9-8904-9FE0C0B95B0F

P577

Q46748103-CCE4BE96-9172-483D-9CAB-DFAE6E131CE0

P698

Q46748103-B834DBCD-B03C-4B1D-A2D3-C4D6ECE096E9

P921

Q46748103-8CB7ADD6-0D48-4EB6-A61A-4357C995478E

Q46748103-9CCCCC26-4404-480C-9C37-5503E12C69D2

P356

JCO.2007.13.6606

P1433

Journal of Clinical Oncology

P1476

Phase III trial of gemcitabine ...... e or recurrent ovarian cancer.

@en

P2093

Antonella Savarese

http://www.w3.org/2001/XMLSchema#string

Dionyssios Katsaros

http://www.w3.org/2001/XMLSchema#string

Domenico Priolo

http://www.w3.org/2001/XMLSchema#string

Enrico Breda

http://www.w3.org/2001/XMLSchema#string

Gabriella Ferrandina

http://www.w3.org/2001/XMLSchema#string

Giovanni Scambia

http://www.w3.org/2001/XMLSchema#string

Laura Scaltriti

http://www.w3.org/2001/XMLSchema#string

Manuela Ludovisi

http://www.w3.org/2001/XMLSchema#string

Pietro Del Medico

http://www.w3.org/2001/XMLSchema#string

P304

890-896

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.13.6606

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Domenica Lorusso

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18281662

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial